Information Provided By: 
Fly News Breaks for July 27, 2015
REGN, ESPR
Jul 27, 2015 | 10:45 EDT
Chardan analyst Gbola Amusa earlier today lowered his price target for Esperion Therapeutics (ESPR) to $40 saying the label for Regeneron's (REGN) Praluent label "reveals multiple negatives" for the company. The FDA has had a policy change by not approving broad use for Praluent, Amusa told investors in a research note. He adds that Esperion's ETC-1002's add-on LDL-lowering ability is "much more modest" than Praluent. The analyst says he has increased conviction in his Sell rating on Esperion.
News For ESPR;REGN From the Last 2 Days
REGN
Apr 25, 2024 | 07:28 EDT
